Dicot to develop LIB-01 to an oral drug
Press release: Uppsala, April 6, 2022. Dicot announces that after evaluating two formulation alternatives, the company decides to prioritize the development of an oral drug candidate for the upcoming phase 1 study. This means that the planned start of the first study in humans is revised to mid-2023. An oral drug is more convenient for patients and means that Dicot's drug candidate will be higher valued in future business negotiations with potential partners.Dicot announced in June 2021 that prior to the initial clinical trials in humans, the company intended to evaluate both subcutaneous